Axcentua Pharmaceuticals AB

Axcentua Pharmaceuticals is an innovative drug discovery and development company located at the Karolinska Institute Science Park. Axcentua is pioneering a unique strategy, crystal reengineering, for accelerated development of novel therapeutics to the clinic with clear benefits for unmet medical needs.

Axcentua’s lead compound, AXP 107-11, is a multi-targeted crystal re-engineered natural compound, currently in clinical trials for pancreatic cancer. AXP107-11 was developed from bench to clinic in only 2 years showing that crystal re-engineering is a unique strategy for accelerated drug development. IP protection of the crystalline form, the crystallization process, composition of matter, and therapeutic use of AXP107-11 is secured through a recent US patent and a pending PCT. Pipeline expansion through novel formulations of AXP107-11 as well as crystal re-engineering of backup candidates is ongoing.

Our development strategy enables fast proof of principle of candidate drugs in the clinic leading to early value enhancement and commercial opportunities.

Axcentua Pharmaceuticals AB
+46 8 524 88 620
http://www.axcentua.se